Suppr超能文献

吸入丙酸倍氯米松可恢复对沙美特罗变应原激发保护作用的耐受性。

Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge.

作者信息

Giannini D, Bacci E, Dente F L, Di Franco A, Vagaggini B, Testi R, Paggiaro P

机构信息

Cardiothoracic Department, University of Pisa, Italy.

出版信息

Chest. 1999 Mar;115(3):629-34. doi: 10.1378/chest.115.3.629.

Abstract

STUDY OBJECTIVE

One week of regular treatment with salmeterol can induce tolerance to the protective effect of a beta2-agonist on early airway response to allergen (EAR). The objective was to assess whether inhaled corticosteroids revert tolerance to salmeterol.

STUDY DESIGN

The study had a randomized, double-blind, placebo-controlled design.

PATIENTS AND METHODS

Twelve subjects with mild allergic asthma and positive result of specific bronchial provocation test (sBPT) to allergen underwent three sBPTs, separated by 1 week. sBPT was done in all subjects after a single dose (T1) and after 1 week of regular treatment with inhaled salmeterol (50 microg bid) (T2) in order to induce tolerance. Subjects were then randomized to receive either the same dose of salmeterol + beclomethasone dipropionate (BDP, 500 microg bid) (group 1, n = 6) or placebo + BDP (group 2, n = 6) for 1 week before sBPT (T3).

RESULTS

After a single dose of salmeterol (T1), all subjects were protected against EAR, whereas after 1 week of regular treatment, the protective effect of salmeterol was totally or partially lost (T2). Maximum FEV1 percent fall (MaxdeltaFEV1%) after allergen inhalation was significantly higher at T2 than at T1. All subjects except one of group 1 were protected against EAR after salmeterol + BDP (T3), and MaxdeltaFEV1% at T3 (median, 12%; range, 4 to 6%) was significantly lower than T2 (median, 22%; range, 12 to 43%; p < 0.05 by Wilcoxon test). Subjects of group 2 did not show any significant protection against EAR after placebo + BDP treatment (T3) MaxdeltaFEV1% at T2 (median, 31%; range, 9 to 40%) and T3 (median, 31%; range, 3 to 42%; not significant).

CONCLUSIONS

In conclusion, the addition of inhaled BDP partially restored the bronchoprotective effect of salmeterol on allergen challenge that was lost after 1 week of regular treatment with salmeterol alone. This ability of BDP in reverting tolerance cannot be ascribed to a direct effect of corticosteroids per se on allergen challenge in this group of asthmatics.

摘要

研究目的

沙美特罗常规治疗一周可诱导对β2受体激动剂对变应原早期气道反应(EAR)保护作用的耐受性。目的是评估吸入性糖皮质激素是否能逆转对沙美特罗的耐受性。

研究设计

本研究采用随机、双盲、安慰剂对照设计。

患者与方法

12名轻度过敏性哮喘且变应原特异性支气管激发试验(sBPT)结果为阳性的受试者接受了3次sBPT,每次间隔1周。所有受试者在单次给药后(T1)以及吸入沙美特罗(50μg,每日两次)常规治疗1周后(T2)进行sBPT,以诱导耐受性。然后,受试者被随机分为两组,在sBPT(T3)前1周,一组接受相同剂量的沙美特罗+二丙酸倍氯米松(BDP,500μg,每日两次)(第1组,n = 6),另一组接受安慰剂+BDP(第2组,n = 6)。

结果

单次给予沙美特罗后(T1),所有受试者对EAR均有保护作用,而在常规治疗1周后,沙美特罗的保护作用完全或部分丧失(T2)。变应原吸入后最大FEV1下降百分比(MaxdeltaFEV1%)在T2时显著高于T1。除第1组的1名受试者外,所有受试者在接受沙美特罗+BDP治疗后(T3)对EAR均有保护作用,且T3时的MaxdeltaFEV1%(中位数为12%;范围为4%至6%)显著低于T2(中位数为22%;范围为12%至43%;Wilcoxon检验,p < 0.05)。第2组受试者在接受安慰剂+BDP治疗后(T3)对EAR未显示出任何显著的保护作用,T2时的MaxdeltaFEV1%(中位数为31%;范围为9%至40%)和T3时的(中位数为31%;范围为3%至42%;无显著差异)。

结论

总之,添加吸入性BDP部分恢复了沙美特罗对变应原激发的支气管保护作用,该作用在单独使用沙美特罗常规治疗1周后丧失。在这组哮喘患者中,BDP逆转耐受性的能力不能归因于糖皮质激素本身对变应原激发的直接作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验